| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis |
NCT03100825: A Long-term Safety Study of QVM149 in Japanese Patients With Asthma |
|
|
| Completed | 3 | 96 | Japan | QVM149, QVM149 150/50/160 μg once daily, delivered as powder in hard capsules via Concept1 inhaler | Novartis Pharmaceuticals | Asthma | 09/18 | 04/19 | | |
| Completed | 3 | 3092 | Europe, Canada, Japan, RoW | QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320, QMF149 150/160, salmeterol/fluticasone | Novartis Pharmaceuticals | Asthma | 06/19 | 06/19 | | |
| Completed | 3 | 1426 | Europe, RoW | QVM149, Salmeterol/fluticasone plus tiotropium | Novartis Pharmaceuticals | Asthma | 07/19 | 07/19 | | |
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium |
|
|
| Not yet recruiting | 3 | 28 | Europe | QMF149, QVM149, Inhalation powder | University Medical Center Groningen, Novartis Pharma AG | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Withdrawn | 3 | 0 | Canada | QVM149, indacaterol acetate/glycopyrronium bromide/mometasone furoate, High Dose Dual Therapy (ICS/LABA) | Dr. Grace Parraga, Novartis Pharmaceuticals | Asthma | 07/22 | 12/22 | | |
| Completed | 3 | 28 | Europe | QVM149, Mometasone/Indacaterol/Glycopyrronium, QMF149, Mometasone/Indacaterol | University Medical Center Groningen, Novartis | Asthma, Allergic Asthma | 12/22 | 12/22 | | |
NCT05776927: A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. |
|
|
| Not yet recruiting | 3 | 304 | NA | QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication, Concept 1 Device, Girohaler | Novartis Pharmaceuticals | Asthma | 03/26 | 08/27 | | |
